Cargando…

Does receiving a SARS-CoV-2 antibody test result change COVID-19 protective behaviors? Testing risk compensation in undergraduate students with a randomized controlled trial

BACKGROUND: Risk compensation, or matching behavior to a perceived level of acceptable risk, can blunt the effectiveness of public health interventions. One area of possible risk compensation during the SARS-CoV-2 pandemic is antibody testing. While antibody tests are imperfect measures of immunity,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ludema, Christina, Rosenberg, Molly S., Macy, Jonathan T., Kianersi, Sina, Luetke, Maya, Chen, Chen, Golzarri-Arroyo, Lilian, Ables, Erin, Maki, Kevin, Allison, David B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9767325/
https://www.ncbi.nlm.nih.gov/pubmed/36538498
http://dx.doi.org/10.1371/journal.pone.0279347
_version_ 1784853941357379584
author Ludema, Christina
Rosenberg, Molly S.
Macy, Jonathan T.
Kianersi, Sina
Luetke, Maya
Chen, Chen
Golzarri-Arroyo, Lilian
Ables, Erin
Maki, Kevin
Allison, David B.
author_facet Ludema, Christina
Rosenberg, Molly S.
Macy, Jonathan T.
Kianersi, Sina
Luetke, Maya
Chen, Chen
Golzarri-Arroyo, Lilian
Ables, Erin
Maki, Kevin
Allison, David B.
author_sort Ludema, Christina
collection PubMed
description BACKGROUND: Risk compensation, or matching behavior to a perceived level of acceptable risk, can blunt the effectiveness of public health interventions. One area of possible risk compensation during the SARS-CoV-2 pandemic is antibody testing. While antibody tests are imperfect measures of immunity, results may influence risk perception and individual preventive actions. We conducted a randomized control trial to assess whether receiving antibody test results changed SARS-CoV-2 protective behaviors. PURPOSE: Assess whether objective information about antibody status, particularly for those who are antibody negative and likely still susceptible to SARS-CoV-2 infection, increases protective behaviors. Secondarily, assess whether a positive antibody test results in decreased protective behaviors. METHODS: In September 2020, we enrolled 1076 undergraduate students, used fingerstick tests for SARS-CoV-2 antibodies, and randomized participants to receive their results immediately or delayed by 4 weeks. Two weeks later, participants completed a survey about their engagement in 4 protective behaviors (mask use, social event avoidance, staying home from work/school, ensuring physical distancing). We estimated differences between conditions for each of these behaviors, stratified by antibody status. For negative participants at baseline, we also estimated the difference between conditions for seroconversion over 8 weeks of follow-up. RESULTS: For the antibody negative participants (n = 1029) and antibody positive participants (n = 47), we observed no significant differences in protective behavior engagement between those who were randomized to receive test results immediately or after 4 weeks. For the baseline antibody negative participants, we also observed no difference in seroconversion outcomes between conditions. CONCLUSIONS: We found that receiving antibody test results did not lead to significant behavior change in undergraduate students whether the SARS-CoV-2 antibody result was positive or negative.
format Online
Article
Text
id pubmed-9767325
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-97673252022-12-21 Does receiving a SARS-CoV-2 antibody test result change COVID-19 protective behaviors? Testing risk compensation in undergraduate students with a randomized controlled trial Ludema, Christina Rosenberg, Molly S. Macy, Jonathan T. Kianersi, Sina Luetke, Maya Chen, Chen Golzarri-Arroyo, Lilian Ables, Erin Maki, Kevin Allison, David B. PLoS One Research Article BACKGROUND: Risk compensation, or matching behavior to a perceived level of acceptable risk, can blunt the effectiveness of public health interventions. One area of possible risk compensation during the SARS-CoV-2 pandemic is antibody testing. While antibody tests are imperfect measures of immunity, results may influence risk perception and individual preventive actions. We conducted a randomized control trial to assess whether receiving antibody test results changed SARS-CoV-2 protective behaviors. PURPOSE: Assess whether objective information about antibody status, particularly for those who are antibody negative and likely still susceptible to SARS-CoV-2 infection, increases protective behaviors. Secondarily, assess whether a positive antibody test results in decreased protective behaviors. METHODS: In September 2020, we enrolled 1076 undergraduate students, used fingerstick tests for SARS-CoV-2 antibodies, and randomized participants to receive their results immediately or delayed by 4 weeks. Two weeks later, participants completed a survey about their engagement in 4 protective behaviors (mask use, social event avoidance, staying home from work/school, ensuring physical distancing). We estimated differences between conditions for each of these behaviors, stratified by antibody status. For negative participants at baseline, we also estimated the difference between conditions for seroconversion over 8 weeks of follow-up. RESULTS: For the antibody negative participants (n = 1029) and antibody positive participants (n = 47), we observed no significant differences in protective behavior engagement between those who were randomized to receive test results immediately or after 4 weeks. For the baseline antibody negative participants, we also observed no difference in seroconversion outcomes between conditions. CONCLUSIONS: We found that receiving antibody test results did not lead to significant behavior change in undergraduate students whether the SARS-CoV-2 antibody result was positive or negative. Public Library of Science 2022-12-20 /pmc/articles/PMC9767325/ /pubmed/36538498 http://dx.doi.org/10.1371/journal.pone.0279347 Text en © 2022 Ludema et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Ludema, Christina
Rosenberg, Molly S.
Macy, Jonathan T.
Kianersi, Sina
Luetke, Maya
Chen, Chen
Golzarri-Arroyo, Lilian
Ables, Erin
Maki, Kevin
Allison, David B.
Does receiving a SARS-CoV-2 antibody test result change COVID-19 protective behaviors? Testing risk compensation in undergraduate students with a randomized controlled trial
title Does receiving a SARS-CoV-2 antibody test result change COVID-19 protective behaviors? Testing risk compensation in undergraduate students with a randomized controlled trial
title_full Does receiving a SARS-CoV-2 antibody test result change COVID-19 protective behaviors? Testing risk compensation in undergraduate students with a randomized controlled trial
title_fullStr Does receiving a SARS-CoV-2 antibody test result change COVID-19 protective behaviors? Testing risk compensation in undergraduate students with a randomized controlled trial
title_full_unstemmed Does receiving a SARS-CoV-2 antibody test result change COVID-19 protective behaviors? Testing risk compensation in undergraduate students with a randomized controlled trial
title_short Does receiving a SARS-CoV-2 antibody test result change COVID-19 protective behaviors? Testing risk compensation in undergraduate students with a randomized controlled trial
title_sort does receiving a sars-cov-2 antibody test result change covid-19 protective behaviors? testing risk compensation in undergraduate students with a randomized controlled trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9767325/
https://www.ncbi.nlm.nih.gov/pubmed/36538498
http://dx.doi.org/10.1371/journal.pone.0279347
work_keys_str_mv AT ludemachristina doesreceivingasarscov2antibodytestresultchangecovid19protectivebehaviorstestingriskcompensationinundergraduatestudentswitharandomizedcontrolledtrial
AT rosenbergmollys doesreceivingasarscov2antibodytestresultchangecovid19protectivebehaviorstestingriskcompensationinundergraduatestudentswitharandomizedcontrolledtrial
AT macyjonathant doesreceivingasarscov2antibodytestresultchangecovid19protectivebehaviorstestingriskcompensationinundergraduatestudentswitharandomizedcontrolledtrial
AT kianersisina doesreceivingasarscov2antibodytestresultchangecovid19protectivebehaviorstestingriskcompensationinundergraduatestudentswitharandomizedcontrolledtrial
AT luetkemaya doesreceivingasarscov2antibodytestresultchangecovid19protectivebehaviorstestingriskcompensationinundergraduatestudentswitharandomizedcontrolledtrial
AT chenchen doesreceivingasarscov2antibodytestresultchangecovid19protectivebehaviorstestingriskcompensationinundergraduatestudentswitharandomizedcontrolledtrial
AT golzarriarroyolilian doesreceivingasarscov2antibodytestresultchangecovid19protectivebehaviorstestingriskcompensationinundergraduatestudentswitharandomizedcontrolledtrial
AT ableserin doesreceivingasarscov2antibodytestresultchangecovid19protectivebehaviorstestingriskcompensationinundergraduatestudentswitharandomizedcontrolledtrial
AT makikevin doesreceivingasarscov2antibodytestresultchangecovid19protectivebehaviorstestingriskcompensationinundergraduatestudentswitharandomizedcontrolledtrial
AT allisondavidb doesreceivingasarscov2antibodytestresultchangecovid19protectivebehaviorstestingriskcompensationinundergraduatestudentswitharandomizedcontrolledtrial